Throughout the last three months, 7 analysts have evaluated Alkermes (NASDAQ:ALKS), offering a diverse set of opinions from ...

The class 2 Elm in Coláiste Chiaráin were chosen to take part in this year’s World of Work Programme which is run in ...

Goldman Sachs analyst Chris Shibutani maintained a Buy rating on Alkermes (ALKS – Research Report) today and set a price target of ...

Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the ...

ALKS stock results show that Alkermes missed analyst estimates for earnings per share and missed on revenue for the first ...

DUBLIN (AP) — DUBLIN (AP) — Alkermes PLC (ALKS) on Wednesday reported first-quarter net income of $36.8 million, after reporting a loss in the same period a year earlier. The Dublin-based company said ...

"The first quarter of 2024 marks our first full quarter as a profitable, pure-play neuroscience company. During the quarter, we continued to advance our strategic priorities acros ...

DUBLIN, Ireland I April 24, 2024 I Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to ...

Alkermes plc (NASDAQ: ALKS) has a price-to-earnings ratio of 11.91x that is above its average ratio. Additionally, the 36-month beta value for ALKS is 0.61. There are mixed opinions on the stock, with ...

Alkermes is preparing for the Vibrance-2 study, which is expected to begin in the latter half of 2024. Credit: Sai Thaw Kyar / Shutterstock. Alkermes has commenced the Vibrance-1 Phase II clinical ...

DUBLIN, April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 ...

DUBLIN, April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared ...